1. EU SmPC
  2. ADVERSE EVENT REPORTING
TAGRISSO® (osimertinib)
  • Home
  • Efficacy
    • OS
    • PFS
    • PFS Subgroups
    • CNS
    • Study design
  • Safety
  • MOA
  • Dosing
  • AURA3
    • PFS
    • CNS
    • Study design
    • Testing
  • Resources
    • AstraZeneca Global Corporate Site
    • Privacy Notice
    • Site Map
    • Legal Statement
    • Cookies
    • Site Map
    • Site Map
    • EU SmPC
    • Adverse Event Reporting
    • Contact Us
    • AstraZeneca Global Corporate Site
    • Privacy Notice
    • Legal Statement
    • Cookies
    • Site Map
    • Site Map
    • EU SmPC
    • Adverse Event Reporting
    • Contact Us

This product information is intended for non-US and non-UK Healthcare Professionals only.

TAGRISSO is a registered trademark of the AstraZeneca group of companies.

©2019 AstraZeneca. All rights reserved.

Date of Prep: December 2019 VEEVA ID: Z4-18665 Expiry Date: December 2021

AstraZeneca